RGDXthe fact that 2Q13 gross margins of 49% is among the highest in oncology testing services group
Is reason enough to buy more here. So I will
Response Genetics target raised to $2.75 at Ladenburg Thalmann as revenue growth gathers momentum
Ladenburg Thalmann raises their RGDX tgt to $2.75 from $1.75 based on the top line growth story, co's competitive cost structure, and the fact that 2Q13 gross margins of 49% is among the highest in oncology testing services group. The firm's core thesis for RGDX remains unchanged: it views co as a restructuring story entering the midpoint of its turnaround strategy.